GW-274150
- Generic Name
- GW-274150
- Drug Type
- Small Molecule
- Chemical Formula
- C8H17N3O2S
- CAS Number
- 210354-22-6
- Unique Ingredient Identifier
- 0ZZF1V8G63
- Background
GW274150 has been used in trials studying the treatment and prevention of Asthma, Migraine, Migraine Disorders, and Arthritis, Rheumatoid.
A Study To Investigate GW274150 Or Prednisolone In Rheumatoid Arthritis Taken Repeatedly For 28 Days.
Phase 2
Completed
- Conditions
- Arthritis, Rheumatoid
- Interventions
- First Posted Date
- 2006-09-25
- Last Posted Date
- 2012-07-02
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 48
- Registration Number
- NCT00379990
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
Study Of 90mg Of GW274150 In Subjects Over 50 Years, Who Have Rheumatoid Arthritis (RA)
Phase 2
Completed
- Conditions
- Arthritis, Rheumatoid
- First Posted Date
- 2006-08-31
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 6
- Registration Number
- NCT00370435
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
An Adaptive Design Trial Of GW274150 In The Treatment Of Acute Migraine
Phase 2
Completed
- Conditions
- Migraine DisordersMigraine
- First Posted Date
- 2006-04-27
- Last Posted Date
- 2012-06-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 126
- Registration Number
- NCT00319137
- Locations
- 🇳🇿
GSK Investigational Site, Wellington, New Zealand
Study With GW274150 In Patients With Mild Asthma
- First Posted Date
- 2006-01-09
- Last Posted Date
- 2017-10-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 28
- Registration Number
- NCT00273013
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
Use Of GW274150 In The Prophylactic Treatment Of Migraine
- First Posted Date
- 2005-10-21
- Last Posted Date
- 2016-05-09
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 430
- Registration Number
- NCT00242866
- Locations
- 🇪🇸
GSK Investigational Site, Valencia, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath